Study protocol for the G-SPIRIT trial: a randomised, placebo-controlled, double-blinded phase III trial of granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury
暂无分享,去创建一个
Masahiko Watanabe | D. Togawa | Yasuo Ito | H. Konishi | A. Sudo | S. Ohtori | K. Fushimi | H. Katoh | Takatoshi Sato | Y. Fujii | T. Hasegawa | Y. Matsuyama | N. Kawahara | H. Hanaoka | S. Inami | T. Aizawa | M. Koda | Koshiro Kamiya | T. Furuya | M. Yamazaki | T. Hirano | Toshihiko Sakakibara | H. Baba | Tetsuya Abe | Yukio Someya | Mitsuhiro Hashimoto | N. Nishida | T. Kanchiku | T. Taguchi | K. Nakanishi | N. Tanaka | K. Akeda | Hidenori Suzuki | M. Funaba | D. Soma | Yoshito Katayama | Tomohiro Matsumoto | Hiroshi Moridaira | T. Ozawa | H. Sameda | S. Nozawa | Michiharu Matsuda | Takehiro Sugaya | H. Imai | Keigo Ito | Sho Kobayashi | N. Kamei | T. Fujiyoshi | Taro Matsumoto | Kei Watanabe | M. Ohashi | S. Osaki | Tatsuki Mizouchi | H. Taneichi | I. Aita | Mitsuhiro Kitamura | T. Banno | Shin Oe | H. Arima | Y. Ikeda | Sho Takahashi | Yosuke Shibao | J. Shimbo | E. Kawamoto | F. Nakajima | M. Mimura | Takayuki Yamaguchi | Tsuyoshi Okudaira | Yukei Matsumoto | Yasushi Ijima | Masaru Idota | Kan Takase | Y. Takeuchi | Daisaku Takeuchi | Haruki Ueda | Futoshi Asano | F. Hasue | Chizuo Iwai | M. Hanawa | H. Shoji | Masahito Kawaguchi | Yugo Orita | T. Sasamoto | M. Yoshioka | M. Fujii | Katsutaka Yonezawa | S. Ikenoue | G. Yoshida | S. Kotaka | H. Kanno | Kokichi Hashimoto | Toshimitsu Eto | T. Kikuchi | I. Takahashi | J. Saito | Yuriko Yamamoto | T. Abe | Shinji Kotaka | Takayuki Fujiyoshi | Daisuke Soma | Ikuo Aita | Shuhei Osaki
[1] A. Hata,et al. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) , 2015, BMJ Open.
[2] W. Waring,et al. Updates for the International Standards for Neurological Classification of Spinal Cord Injury. , 2014, Physical medicine and rehabilitation clinics of North America.
[3] Yasuo Ito,et al. Multicenter Prospective Nonrandomized Controlled Clinical Trial to Prove Neurotherapeutic Effects of Granulocyte Colony-Stimulating Factor for Acute Spinal Cord Injury: Analyses of Follow-up Cases After at Least 1 Year , 2014, Spine.
[4] N. Theodore,et al. Pharmacological therapy for acute spinal cord injury. , 2013, Neurosurgery.
[5] Kazuhisa Takahashi,et al. Granulocyte Colony-Stimulating Factor (G-CSF) Protects Oligpdendrocyte and Promotes Hindlimb Functional Recovery after Spinal Cord Injury in Rats , 2012, PloS one.
[6] A. Catz,et al. Development and validation of a self-report version of the Spinal Cord Independence Measure (SCIM III) , 2012, Spinal Cord.
[7] Yasuo Ito,et al. Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trial , 2012, European Spine Journal.
[8] M. Koda,et al. Neuroprotective effects of granulocyte colony-stimulating factor and relationship to promotion of angiogenesis after spinal cord injury in rats: laboratory investigation. , 2011, Journal of neurosurgery. Spine.
[9] S. Okada,et al. Granulocyte Colony-Stimulating Factor Attenuates Neuronal Death and Promotes Functional Recovery After Spinal Cord Injury in Mice , 2007, Journal of neuropathology and experimental neurology.
[10] S. Okada,et al. Granulocyte colony-stimulating factor (G-CSF) mobilizes bone marrow-derived cells into injured spinal cord and promotes functional recovery after compression-induced spinal cord injury in mice , 2007, Brain Research.
[11] Hung Li,et al. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial , 2006, Canadian Medical Association Journal.
[12] H. Okano,et al. Administration of Hematopoietic Cytokines in the Subacute Phase After Cerebral Infarction Is Effective for Functional Recovery Facilitating Proliferation of Intrinsic Neural Stem/Progenitor Cells and Transition of Bone Marrow–Derived Neuronal Cells , 2006, Circulation.
[13] Tobias Steigleder,et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. , 2005, The Journal of clinical investigation.
[14] A. Roberts. G-CSF: A key regulator of neutrophil production, but that's not all! , 2005, Growth factors.
[15] Munehito Yoshida,et al. Early Complications of High-Dose Methylprednisolone Sodium Succinate Treatment in the Follow-Up of Acute Cervical Spinal Cord Injury , 2001, Spine.
[16] W. Collins,et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. , 1991, The New England journal of medicine.
[17] N. Nicola,et al. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. , 1983, The Journal of biological chemistry.
[18] G. Hawryluk,et al. Pharmacologic Management of Acute Spinal Cord Injury. , 2017, Neurosurgery clinics of North America.
[19] C. Oyinbo. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. , 2011, Acta neurobiologiae experimentalis.
[20] N. Nicola. Granulocyte-colony stimulating factor , 1990, Immunology series.